The AMZ2 knockout HT29 polyclonal cells are a CRISPR/Cas9-edited human colorectal adenocarcinoma cell population featuring targeted disruption of the gene encoding AMZ2, a zinc-dependent metalloprotease. This polyclonal pool offers a heterogeneous loss-of-function model suitable for functional analyses of AMZ2 in an intestinal epithelial cell context, without reliance on single-cell clones. The cells are provided as a ready-to-use polyclonal knockout product, generated using CRISPR/Cas9-mediated gene disruption, and are intended for advanced biomedical research applications.
HT29 is a well-established human colorectal adenocarcinoma cell line with epithelial morphology, originally isolated from a primary colon tumor. These cells serve as a widely used in vitro model for studying intestinal epithelial biology, including barrier function, differentiation, and carcinogenesis. The HT29 background provides a relevant platform for examining mitochondrial proteolytic pathways within a colorectal cancer setting, offering insight into how mitochondrial protein quality control influences tumor cell physiology.
AMZ2 encodes a mitochondrial matrix zinc metalloprotease that plays a critical role in the processing of nuclear-encoded mitochondrial precursor proteins upon their import. Acting downstream of mitochondrial import signals and cellular stress pathways, AMZ2 interacts with mitochondrial processing peptidases and molecular chaperones such as HSP60 and mtHsp70 to cleave precursor polypeptides into mature, functional proteins. This activity is essential for maintaining mitochondrial proteostasis and proper protein maturation, with AMZ2 contributing to the generation of processed mitochondrial peptides that support metabolic and stress-adaptive functions.
In the HT29 colorectal adenocarcinoma background, disruption of AMZ2 provides a physiologically pertinent model for dissecting the role of mitochondrial proteolysis in cancer cell metabolism and stress responses. Colorectal cancer cells frequently exhibit altered mitochondrial dynamics and heightened proteostatic demand; thus, AMZ2 knockout allows assessment of how impaired precursor processing impacts energy metabolism, redox balance, and cell survival under conditions such as nutrient deprivation or chemotherapeutic stress. The polyclonal nature preserves cellular heterogeneity, enabling robust population-level analyses of mitochondrial dysfunction.
This knockout product is well-suited for a range of research applications, including functional studies of mitochondrial proteolysis, cancer cell metabolism, and mitochondrial stress responses. Representative assays include Western blotting to evaluate mitochondrial protein processing, immunofluorescence for mitochondrial localization of AMZ2 substrates, mitochondrial stress response assays using uncouplers or ATP synthase inhibitors, and protease activity measurements. The polyclonal HT29 AMZ2 knockout cells can also be employed in drug screening to uncover mitochondrial vulnerabilities in colorectal cancer. For additional technical specifications or to inquire about further details, please contact Ascent Research’s scientific support team.
